![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Enzyvant Draws Complete Response Letter for Regenerative Therapy
Enzyvant Draws Complete Response Letter for Regenerative Therapy
December 19, 2019
The FDA hit Enzyvant with a complete response letter for its regenerative tissue therapy RVT-802, an investigational drug for a rare immunodeficiency disorder.
The agency raised concerns about the manufacturing process for the product and other issues identified during an inspection of the manufacturing site.
RVT-802 is a tissue-based regenerative therapy designed to treat primary immune deficiency resulting from pediatric congenital athymia, which affects babies born without a thymus gland.
The FDA accepted the company’s BLA for RVT-802 in June and granted it several designations, including rare pediatric disease and orphan drug statuses. RVT-802 was also granted breakthrough therapy designation and was expected to be approved this month.
Upcoming Events
-
21Oct